Table 2.
Patients’ characteristics and clinicopathological feature in subgroup analysis.
| a) Metastatic de-novo versus metastatic recurrent | |||
| Metastatic recurrent (n = 26) | Metastatic de-novo (n = 10) | P value | |
| Age median (range), (y.o.) | 51 (33-74) | 49 (35-64) | 0.344 |
| Subtype | 0.079 | ||
| Luminal | 19 (73.1%) | 10 (100%) | |
| Triple negative | 7 (26.9%) | 0 (0%) | |
| Number of previous chemotherapy regimens, (n) | 0.515 | ||
| 0 | 17 (65.4%) | 5 (50.0%) | |
| 1 | 6 (27.3%) | 4 (40.0%) | |
| 2 | 1 (3.8%) | 1 (10.0%) | |
| ≧3 | 2 (7.7%) | 0 (0%) | |
| Previous endocrine therapy, (n) | 16 (61.5%) | 10 (100%) | 0.021 |
| Metastatic sites, (n) | 0.473 | ||
| Visceral | 16 (61.5%) | 7 (70.0%) | |
| Non-visceral | 10 (27.8%) | 3 (30.0%) | |
| b) No prior chemotherapy (CT) versus after chemotherapy. | |||
| No primary CT (n = 22) | After CT (n = 14) | P value | |
| Age median (range), (y.o.) | 51 (34-74) | 47 (33-73) | 0.243 |
| Metastatic de-novo or recurrent, (n) | 0.318 | ||
| Metastatic de-novo | 5 (22.7%) | 5 (35.7%) | |
| Metastatic recurrent | 17 (77.3%) | 9 (64.3%) | |
| Subtype | 0.433 | ||
| Luminal | 17 (77.3%) | 12 (85.7%) | |
| Triple negative | 5 (22.7%) | 2 (14.3%) | |
| Previous endocrine therapy, (n) | 16 (72.7%) | 10 (71.4%) | 0.611 |
| Metastatic sites, (n) | 0.374 | ||
| Visceral | 15 (68.2%) | 8 (57.1%) | |
| Non-visceral | 7 (31.8%) | 6 (42.9%) | |
| c) Visceral metastasis versus non-visceral metastasis. | |||
| Visceral metastasis (n = 23) | Non-visceral metastasis (n = 13) | P value | |
| Age median (range), (y.o.) | 51.5 (33-73) | 48 (34-74) | 0.135 |
| Metastatic de-novo or recurrent, (n) | 0.473 | ||
| Metastatic de-novo | 7 (30.4%) | 3 (23.1%) | |
| Metastatic recurrent | 16 (69.6%) | 10 (76.9%) | |
| Subtype | 0.499 | ||
| Luminal | 19 (82.6%) | 10 (76.9%) | |
| Triple negative | 4 (17.4%) | 3 (23.1%) | |
| Number of previous chemotherapy regimens, (n) | 0.920 | ||
| 0 | 14 (60.9%) | 8 (61.5%) | |
| 1 | 7 (30.4%) | 3 (23.1%) | |
| 2 | 1 (4.3%) | 1 (7.7%) | |
| ≧3 | 1 (4.3%) | 1 (7.7%) | |
| Previous endocrine therapy, (n) | 18 (78.3%) | 8 (61.5%) | 0.420 |
| d) Luminal type versus triple negative breast cancer. | |||
| Luminal (n = 29) | TN (n = 7) | P value | |
| Age median (range), (y.o.) | 50 (33-74) | 58 (36-73) | 0.219 |
| Metastatic de-novo or recurrent, (n) | 0.079 | ||
| Metastatic de-novo | 10 (22.7%) | 0 (35.7%) | |
| Metastatic recurrent | 19 (77.3%) | 7 (64.3%) | |
| Number of previous chemotherapy regimens, (n) | 0.773 | ||
| 0 | 17 (60.9%) | 5 (61.5%) | |
| 1 | 8 (30.4%) | 2 (23.1%) | |
| 2 | 2 (4.3%) | 0 (7.7%) | |
| ≧3 | 2 (4.3%) | 0 (7.7%) | |
| Metastatic sites, (n) | 0.499 | ||
| Visceral | 19 (68.2%) | 4 (57.1%) | |
| Non-visceral | 10 (31.8%) | 3 (42.9%) | |
| Metastatic recurrent (n = 19) | Metastatic de-novo (n = 10) | P value | |
| Age median (range), (y.o.) | 50 (33-74) | 49 (35-64) | 0.618 |
| Number of previous chemotherapy regimens, (n) | 0.510 | ||
| 0 | 12 (65.4%) | 5 (50.0%) | |
| 1 | 4 (27.3%) | 4 (40.0%) | |
| 2 | 1 (3.8%) | 1 (10.0%) | |
| ≧3 | 2 (7.7%) | 0 (0%) | |
| Previous endocrine therapy, (n) | 15 (61.5%) | 10 (100%) | 0.163 |
| Metastatic sites, (n) | 0.522 | ||
| Visceral | 12 (61.5%) | 7 (70.0%) | |
| Non-visceral | 7 (27.8%) | 3 (30.0%) | |